AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

Claim 1 (currently amended): A compound having the formula:

$$R^3$$
 R^1
 X
 Y
 R^2

wherein

Ar¹ is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl;

X is a divalent linkage selected from the group consisting of (C_1-C_6) alkylene, (C_1-C_6) alkylenoxy, (C_1-C_6) alkylenamino, (C_1-C_6) alkylene $S(O)_k$ -, -O-, -C(O)-, -N(R¹¹)-, -N(R¹¹)C(O)-, -S(O)_k- and -CH₂- a single bond,

wherein

 R^{11} is a member selected from the group consisting of hydrogen, (C_1 - C_8)alkyl, (C_2 - C_8)heteroalkyl and aryl(C_1 - C_4)alkyl; and the subscript k is an integer of from 0 to 2;

Y is $N(R^{12})-S(O)_{m^{-}}$,

wherein

 R^{12} is independently selected from the group consisting of hydrogen, (C_1 - C_8)alkyl, (C_2 - C_8)heteroalkyl and aryl(C_1 - C_4)alkyl; and the subscripts m and n are independently integers of from 0 to 2:

 R^1 is a member selected from the group consisting of hydrogen, (C₂-

 C_8)heteroalkyl, aryl, aryl(C_1 - C_4)alkyl, halogen, cyano, nitro, (C_1 - C_8)alkyl, (C_1 - C_8)alkoxy, - $C(O)R^{14}$, - CO_2R^{14} , - $C(O)NR^{15}R^{16}$, - $S(O)_p$ - R^{14} , - $S(O)_q$ - $NR^{15}R^{16}$, -O-C(O)- OR^{17} , -O-C(O)- R^{17} , - R^{16} , - R^{1

wherein

 R^{14} is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl, aryl and aryl(C₁-C₄)alkyl;

 R^{15} and R^{16} are members independently selected from the group consisting of hydrogen, (C_1 - C_8)alkyl, (C_2 - C_8)heteroalkyl, aryl, and aryl(C_1 - C_4)alkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;

 R^{17} is a member selected from the group consisting of (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl, aryl and aryl(C₁-C₄)alkyl;

the subscript p is an integer of from 0 to 3; and the subscript q is an integer of from 1 to 2; and

R2 is a substituted or unsubstituted aryl; and

 R^3 is a member selected from the group consisting of halogen, cyano, nitro and (C_1-C_8) alkoxy;

or a pharmaceutically acceptable salt of the compound.

Claim 2 (previously presented): A compound of claim 1, wherein R² is a substituted or unsubstituted aryl selected from the group consisting of phenyl, pyridyl, naphthyl and pyridazinyl.

Claim 3 (original): A compound of claim 2, wherein Ar¹ is a substituted or unsubstituted phenyl group.

Claim 4 (original): A compound of claim 3, represented by a formula selected from the group consisting of

$$Ar^{1} \times R^{2} \times R^{$$

Claim 5 (original): A compound of claim 3, represented by a formula selected from the group consisting of

Claim 6 (currently amended): A compound of claim 5, wherein

X is a divalent linkage selected from the group consisting of $-CH_2$ -, $-CH(CH_3)$ -, -O-, -C(O)-, $-N(R^{11})$ -and -S-;

wherein

R¹¹-is a member selected from the group consisting of hydrogen and (C₁-C₈)alkyl;

Y is $-N(R^{12})-S(O)_2-$,

wherein

 R^{12} is a member selected from the group consisting of hydrogen and (C₁-C₈)alkyl;

 R^{1} is a member selected from the group consisting of hydrogen, halogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl, (C₁-C₈)alkoxy, -C(O)R¹⁴, -CO₂R¹⁴, -C(O)NR¹⁵R¹⁶, -S(O)_p-R¹⁴, -S(O)_q-NR¹⁵R¹⁶, -O-C(O)-R¹⁷, and -N(R¹⁴)-C(O)-R¹⁷:

wherein

 R^{14} is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl, hetero(C₁-C₈)alkyl, aryl and aryl(C₁-C₄)alkyl;

 R^{15} and R^{16} are members independently selected from the group consisting of hydrogen, (C_1 - C_8)alkyl and (C_2 - C_8)heteroalkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;

 R^{17} is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl and (C₂-C₈)heteroalkyl;

the subscript p is an integer of from 0 to 2; and

the subscript q is 2; and

R² is a substituted or unsubstituted phenyl; and

R³ is a member selected from the group consisting of halogen and (C₁-C₈)alkoxy.

Claim 7 (currently amended): A compound of claim 6, wherein X is -O-, -NH- or -S-; Y is -NH-SO₂-; R¹ is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl, (C_1-C_8) alkoxy, $-C(O)R^{14}$, $-CO_2R^{14}$, $-CO_2R^{14}$, $-CO_2R^{16}$, $-S(O)_p$ -R¹⁴ and $-S(O)_q$ -NR¹⁵R¹⁶; R² is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, -C(O)- (C_1-C_8) alkyl, -CN, $-CF_3$, (C_1-C_8) alkyl and $-NH_2$; and R³ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 8 (previously presented): A compound of claim 7, wherein Ar^1 is a phenyl group having from 1 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_6)$ alkyl, $-CF_3$, (C_1-C_8) alkyl and $-NO_2$; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl and (C_1-C_8) alkoxy; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, -C(O)- $-(C_1-C_8)$ alkyl, -CN, $-CF_3$, -CN, $-CF_3$, -CN, $-CC_8$ -alkyl and $-NH_2$; and $-NH_2$; and $-NH_2$ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claims 9 - 14 (canceled).

Claim 15 (original): A compound of claim 2, wherein Ar¹ is a substituted or unsubstituted naphthyl group.

Claim 16 (original): A compound of claim 15, represented by a formula selected from the group consisting of

$$Ar^{1} \xrightarrow{R^{3}} R^{2}, \quad Ar^{1} \xrightarrow{R^{1}} R^{3}, \quad Ar^{1} \xrightarrow{R^{1}} R^{3}, \quad Ar^{1} \xrightarrow{R^{2}} R^{3}, \quad Ar^{1} \xrightarrow{R^{2}} R^{3}, \quad Ar^{1} \xrightarrow{R^{2}} R^{3}, \quad Ar^{1} \xrightarrow{R^{2}} R^{1}, \quad Ar^{1} \xrightarrow{R^{2}} R^{1}, \quad Ar^{1} \xrightarrow{R^{3}} R^{$$

Claim 17 (original): A compound of claim 16, represented by a formula selected from the group consisting of

Claim 18 (currently amended): A compound of claim 17, wherein

X is a divalent linkage selected from the group consisting of $-CH_2$ -, $-CH(CH_3)$ -, -O-, -C(O)-, $-N(R^{11})$ - and -S-;

wherein

 R^{11} is a member selected from the group consisting of hydrogen and (C₁-C₈)alkyl;

Y is $-N(R^{12})-S(O)_2-$,

wherein

 R^{12} is a member selected from the group consisting of hydrogen and (C_1-C_8) alkyl;

 R^1 is a member selected from the group consisting of hydrogen, halogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl, (C₁-C₈)alkoxy, -C(O)R¹⁴, -CO₂R¹⁴, -C(O)NR¹⁵R¹⁶, -S(O)_p-R¹⁴, -S(O)_q-NR¹⁵R¹⁶, -O-C(O)-R¹⁷, and -N(R¹⁴)-C(O)-R¹⁷:

wherein

 R^{14} is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl, hetero(C₁-C₈)alkyl, aryl and aryl(C₁-C₄)alkyl;

R¹⁵ and R¹⁶ are members independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl and (C₂-C₈)heteroalkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;

 R^{17} is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl and (C₂-C₈)heteroalkyl;

the subscript p is an integer of from 0 to 2; and

the subscript q is 2; and

R² is a substituted or unsubstituted phenyl; and

R³ is a member selected from the group consisting of halogen and (C₁-C₈)alkoxy.

Claim 19 (currently amended): A compound of claim 18, wherein X is - O-, -NH-or -S-; Y is -NH-SO₂-; R¹ is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl, (C_1-C_8) alkoxy, $-C(O)R^{14}$, $-CO_2R^{14}$, - $C(O)NR^{15}R^{16}$, $-S(O)_p-R^{14}$ and $-S(O)_q-NR^{15}R^{16}$; R² is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, - $C(O)-(C_1-C_8)$ alkyl, -CN, $-CF_3$, (C_1-C_8) alkyl and $-NH_2$; and R³ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 20 (original): A compound of claim 19, wherein Ar^1 is a naphthyl group having from 1 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_6)$ alkyl, $-CF_3$, (C_1-C_8) alkyl and $-NO_2$; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl and (C_1-C_8) alkoxy; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, -C(O)- $-(C_1-C_8)$ alkyl, -CN, $-CF_3$, $-CF_3$, $-CF_3$, $-CF_3$, and $-CF_3$ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claims 21-54 (canceled).

Claim 55 (previously presented): A compound of claim 2, wherein R² is substituted phenyl.

Claim 56 (previously presented): A compound of claim 7, wherein X is -O-.

Claim 57 (previously presented): A compound of claim 7, wherein X is -S-.

Claim 58 (previously presented): A compound of claim 7, wherein the compound is of formula Ii.

Claim 59 (previously presented): A compound of claim 15, wherein Ar¹ is unsubstituted naphthyl.

Claim 60 (previously presented): A compound of claim 19, wherein X is -S-.

Claim 61 (previously presented): A compound of claim 19, wherein X is -O-.

Claim 62 (previously presented): A compound of claim 19, wherein the compound is of formula Ii.

Claim 63 (currently amended): A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:

$$Ar^1$$

wherein

Ar¹ is a substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl;

X is a divalent linkage selected from the group consisting of (C₁-C₆)alkylene, (C₁-

 C_6)alkylenoxy, (C_1-C_6) alkylenamino, (C_1-C_6) alkylene- $S(O)_k$ -, -O-, -C(O)-, - $N(R^{11})$ -, $N(R^{11})$ -, $N(R^{11})$ -, -S(O)_k- and -CH₂- a single bond,

wherein

 R^{11} is a member selected from the group consisting of hydrogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl and aryl (C_1-C_4) alkyl; and the subscript k is an integer of from 0 to 2;

Y is N(R¹²)-S(O)_m-, wherein

 R^{12} is independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl and aryl(C₁-C₄)alkyl; and the subscripts m and n are independently integers of from 0 to 2;

 R^{1} is a member selected from the group consisting of hydrogen, $(C_{2}\text{-}C_{8})$ heteroalkyl, aryl, aryl(C1-C4)alkyl, halogen, cyano, nitro, $(C_{1}\text{-}C_{8})$ alkyl, $(C_{1}\text{-}C_{8})$ alkoxy, - $C(O)R^{14}$, - $CO_{2}R^{14}$, - $C(O)NR^{15}R^{16}$, - $S(O)_{p}\text{-}R^{14}$, - $S(O)_{q}\text{-}NR^{15}R^{16}$, - $O\text{-}C(O)\text{-}OR^{17}$, - $O\text{-}C(O)\text{-}NR^{15}R^{16}$, - $N(R^{14})\text{-}C(O)\text{-}NR^{15}R^{16}$, - $N(R^{14})\text{-}C(O)\text{-}NR^{17}$ and - $N(R^{14})\text{-}C(O)\text{-}OR^{17}$:

wherein

R¹⁴ is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl, aryl and aryl(C₁-C₄)alkyl;

 R^{15} and R^{16} are members independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl, aryl, and aryl(C₁-C₄)alkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;

 R^{17} is a member selected from the group consisting of $(C_1\text{-}C_8)$ alkyl, $(C_2\text{-}C_8)$ heteroalkyl, aryl and aryl $(C_1\text{-}C_4)$ alkyl; the subscript p is an integer of from 0 to 3; and the subscript q is an integer of from 1 to 2; and R^2 is a substituted or unsubstituted aryl; and

 R^3 is a member selected from the group consisting of halogen, cyano, nitro and $(C_1\text{-}C_8)$ alkoxy;

or a pharmaceutically acceptable salt of the compound.

Claim 64 (previously presented): A composition of claim 63, wherein R² is a substituted or unsubstituted aryl selected from the group consisting of phenyl, pyridyl, naphthyl and pyridazinyl.

Claim 65 (previously presented): A composition of claim 64, wherein Ar¹ is a substituted or unsubstituted phenyl group.

Claim 66 (currently amended): A composition of claim 65, wherein the compound is represented by a formula selected from the group consisting of

$$R^{3}$$
 Ar^{1}
 R^{1}
 R^{2}
 R^{3}
 X
 Ar^{1}
(Ii)
(Ij)

and wherein X is -O—, -NH— or -S-; Y is -NH- SO_2 -; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl, (C_1-C_8) alkoxy, $-C(O)R^{14}$, $-CO_2R^{14}$, $-C(O)NR^{15}R^{16}$, $-S(O)_p$ - R^{14} and $-S(O)_q$ - $NR^{15}R^{16}$; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, -C(O)- $-(C_1-C_8)$ alkyl, -CN, $-CF_3$, -CI-

Claim 67 (previously presented): A composition of claim 66, wherein Ar^1 is a phenyl group having from 1 to 3 substituents selected from the group consisting of halogen, - OCF₃, -OH, -O(C₁-C₆)alkyl, -CF₃, (C₁-C₈)alkyl and -NO₂; R^1 is a member selected from the group consisting of halogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl and (C₁-C₈)alkoxy; R^2 is a

phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, - OCF_3 , -OH, -O(C₁-C₈)alkyl, -C(O)-(C₁-C₈)alkyl, -CN, -CF₃, (C₁-C₈)alkyl and -NH₂; and R³ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 68 (previously presented): A composition of claim 67, wherein the compound is of formula Ii.

Claim 69 (previously presented): A composition of claim 63, wherein Ar¹ is substituted or unsubstituted naphthyl group.

Claim 70 (currently amended): A composition of claim 69, wherein the compound is represented by a formula selected from the group consisting of

and wherein X is -O-, -NH- or -S-; Y is -NH- SO_2 -; R^1 is a member selected from the group consisting of halogen, $(C_1$ - $C_8)$ alkyl, $(C_2$ - $C_8)$ heteroalkyl, $(C_1$ - $C_8)$ alkoxy, $-C(O)R^{14}$, $-CO_2R^{14}$, $-C(O)NR^{15}R^{16}$, $-S(O)_p$ - R^{14} and $-S(O)_q$ - $NR^{15}R^{16}$; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1$ - $C_8)$ alkyl, -C(O)- $(C_1$ - $C_8)$ alkyl, -CN, $-CF_3$, $(C_1$ - $C_8)$ alkyl and $-NH_2$; and R^3 is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 71 (previously presented): A composition of claim 70, wherein Ar^1 is a naphthyl group having from 1 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_6)$ alkyl, $-CF_3$, (C_1-C_8) alkyl and $-NO_2$; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl and (C_1-C_8) alkoxy; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, $-C(O)-(C_1-C_8)$ alkyl, -CN, $-CF_3$, (C_1-C_8) alkyl and $-NH_2$; and R^3 is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 72 (previously presented): A composition of claim 71, wherein the compound is of formula Ii.

Claim 73 (withdrawn; currently amended): A method for modulating conditions associated with metabolic or inflammatory disorders in a host, said method comprising administering to said host an efficacious amount of a compound having the formula:

$$R^3$$
 R^1
 X
 Y
 R^2

wherein

Ar¹ is a substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl;

X is a divalent linkage selected from the group consisting of (C_1-C_6) alkylene, (C_4-C_6)

 C_6)alkylenoxy, (C_1-C_6) alkylenamino, (C_1-C_6) alkylene- $S(O)_k$ -, -O-, -C(O)-, - $N(R^{11})$ -, $-N(R^{11})$ C(O)-, -S(O)_k- and -CH₂- a single bond,

wherein

 R^{11} is a member selected from the group consisting of hydrogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl and aryl(C₁-C₄)alkyl; and the subscript k is an integer of from 0 to 2;

Y is $N(R^{12})$ - $S(O)_m$ -, wherein

 R^{12} is independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl, (C₂-C₈)heteroalkyl and aryl(C₁-C₄)alkyl; and the subscripts m

and n are independently integers of from 0 to 2;

 R^{1} is a member selected from the group consisting of hydrogen, $(C_{2}\text{-}C_{8})$ heteroalkyl, aryl, aryl(C1-C4)alkyl, halogen, cyano, nitro, $(C_{1}\text{-}C_{8})$ alkyl, $(C_{1}\text{-}C_{8})$ alkoxy, - $C(O)R^{14}$, - $CO_{2}R^{14}$, - $C(O)NR^{15}R^{16}$, - $S(O)_{p}\text{-}R^{14}$, - $S(O)_{q}\text{-}NR^{15}R^{16}$, - $O\text{-}C(O)\text{-}OR^{17}$, - $O\text{-}C(O)\text{-}NR^{15}R^{16}$, - $N(R^{14})\text{-}C(O)\text{-}NR^{15}R^{16}$, - $N(R^{14})\text{-}C(O)\text{-}NR^{17}$ and - $N(R^{14})\text{-}C(O)\text{-}OR^{17}$;

wherein

 R^{14} is a member selected from the group consisting of hydrogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl, aryl and aryl (C_1-C_4) alkyl;

 R^{15} and R^{16} are members independently selected from the group consisting of hydrogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl, aryl, and aryl (C_1-C_4) alkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;

 R^{17} is a member selected from the group consisting of (C₁-C₈)alkyl, (C₂-

 C_8)heteroalkyl, aryl and aryl(C_1 - C_4)alkyl; the subscript p is an integer of from 0 to 3; and the subscript q is an integer of from 1 to 2; and R^2 is a substituted or unsubstituted aryl; and

 R^3 is a member selected from the group consisting of halogen, cyano, nitro and $(C_1\text{-}C_8)$ alkoxy;

or a pharmaceutically acceptable salt of the compound.

Claim 74 (withdrawn): The method of claim 73, wherein R² is a substituted or unsubstituted aryl selected from the group consisting of phenyl, pyridyl, naphthyl and pyridazinyl.

Claim 75 (withdrawn): The method of claim 73, wherein Ar¹ is a substituted or unsubstituted phenyl group.

Claim 76 (withdrawn; currently amended): The method of claim 75, wherein the compound is represented by a formula selected from the group consisting of

$$R^3$$
 R^2
 R^1
 R^2
 R^3
 R^4
 R^3
 R^4
 R^3
 R^4
 R^3
 R^4
 R^3
 R^4
 R^4
 R^5
 R^6

and wherein X is -O-, -NH- or -S-; Y is -NH- SO_2 -; R^1 is a member selected from the group consisting of halogen, $(C_1$ - C_8)alkyl, $(C_2$ - C_8)heteroalkyl, $(C_1$ - C_8)alkoxy, $-C(O)R^{14}$, $-CO_2R^{14}$, $-C(O)NR^{15}R^{16}$, $-S(O)_p$ - R^{14} and $-S(O)_q$ - $NR^{15}R^{16}$; R^2 is a phenyl group having from 0 to 3 substitutents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1$ - C_8)alkyl, -C(O)- $(C_1$ - C_8)alkyl, -CN, $-CF_3$, $(C_1$ - C_8)alkyl and $-NH_2$; and R^3 is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 77 (withdrawn): The method of claim 76, wherein Ar^1 is a phenyl group having from 1 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_6)$ alkyl, $-CF_3$, (C_1-C_8) alkyl and $-NO_2$; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl and (C_1-C_8) alkoxy; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -

OH, $-O(C_1-C_8)$ alkyl, $-C(O)-(C_1-C_8)$ alkyl, -CN, $-CF_3$, (C_1-C_8) alkyl and $-NH_2$; and R^3 is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 78 (withdrawn): The method of claim 77, wherein the compound is of formula Ii.

Claim 79 (withdrawn): The method of claim 73, wherein Ar¹ is a substituted or unsubstituted naphthyl group.

Claim 80 (withdrawn; currently amended): The method of claim 79, wherein the compound represented by a formula selected from the group consisting of

$$R^3$$
 Ar^1
 R^1
 R^2
 Ar^1
 R^3
 R^3
 R^4
 R^2
 R^3
 R^3
 R^4
 R^2
 R^3
 R^4
 R^3
 R^4
 R^5

and wherein X is -O-, -NH- or -S-; Y is -NH- SO_2 -; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl, (C_1-C_8) alkoxy, $-C(O)R^{14}$, $-CO_2R^{14}$, $-C(O)NR^{15}R^{16}$, $-S(O)_p-R^{14}$ and $-S(O)_q-NR^{15}R^{16}$; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, -C(O)- $-(C_1-C_8)$ alkyl, -CN, $-CF_3$, $-C(C_1-C_8)$ alkyl and $-NH_2$; and $-NH_2$; and $-NH_2$ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 81 (withdrawn): The method of claim 80, wherein Ar^1 is a naphthyl group having from 1 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_6)$ alkyl, $-CF_3$, (C_1-C_8) alkyl and $-NO_2$; R^1 is a member selected from the group consisting of halogen, (C_1-C_8) alkyl, (C_2-C_8) heteroalkyl and (C_1-C_8) alkoxy; R^2 is a phenyl group having from 0 to 3 substituents selected from the group consisting of halogen, $-OCF_3$, -OH, $-O(C_1-C_8)$ alkyl, -C(O)- $-(C_1-C_8)$ alkyl, -CN, $-CF_3$, $-CF_3$, $-CF_3$, $-CF_3$, alkyl and $-NH_2$; and $-NH_3$ is selected from the group consisting of halogen, methoxy and trifluoromethoxy.

Claim 82 (withdrawn): The method of claim 81, wherein the compound is of formula Ii.

Claim 83 (withdrawn): The method of claim 73, wherein said host is a mammal selected from the group consisting of humans, dogs, monkeys, mice, rats, horses and cats.

Claim 84 (withdrawn): The method of claim 73, wherein said administering is oral.

Claim 85 (withdrawn): The method of claim 73, wherein said disorders are selected from the group consisting of NIDDM, obesity, hypercholesterolemia and inflammatory conditions.

Claim 86 (withdrawn): The method of claim 85, wherein said metabolic disorders are mediated by PPAR γ .